• Morning Training Promotes Superior Endurance Adaptation in M

  2026-06-08

  Recent research demonstrates that morning endurance training leads to greater performance adaptations in mice compared to afternoon training, despite lower training volumes. These results highlight the importance of exercise timing in experimental design for metabolic and circadian biology studies.

• Cholesterol Impedes Lipid Nanoparticle Intracellular Traffic

  2026-06-08

  A recent study reveals that elevated cholesterol in lipid nanoparticles (LNPs) hinders their intracellular trafficking and reduces nucleic acid delivery efficiency. By dissecting LNP composition effects, the research offers mechanistic insights vital for optimizing nonviral delivery systems in molecular biology.

• Live-Dead Bacterial Staining Kit: Precision Viability Workfl

  2026-06-07

  Unlock dual-color, quantitative assessment of bacterial viability in advanced infection and nanomaterial research. This guide details stepwise protocols, troubleshooting, and real-world enhancements that leverage the APExBIO Live-Dead Bacterial Staining Kit for robust, reproducible results.

• FLOT1-FOSL2-EphA2 Axis Regulates Microglial Inflammation in

  2026-06-06

  This study reveals that the interaction between FLOT1 and FOSL2 upregulates EphA2 transcription, activating the p38/MAPK pathway and driving pro-inflammatory microglial polarization in Alzheimer’s disease. Disrupting this axis reduces neuroinflammation and improves cognitive outcomes, highlighting a new therapeutic target for neurodegeneration research.

• Lanabecestat (AZD3293): Applied BACE1 Inhibition in AD Model

  2026-06-05

  Lanabecestat (AZD3293) offers precision BACE1 inhibition with robust blood-brain barrier penetration, empowering Alzheimer's disease research with controlled amyloid-beta pathway modulation. This article provides advanced experimental workflows, troubleshooting tactics, and key insights from recent translational studies, setting Lanabecestat apart for reproducible neurodegeneration research.

• Berberine Hydrochloride Induces Tuft Cell Expansion to Preve

  2026-06-05

  This study reveals that berberine hydrochloride counteracts estrogen deficiency-induced bone loss by promoting intestinal tuft cell expansion through a butyrate-GPR41 pathway. The research underscores a novel gut–bone axis mechanism, suggesting practical directions for postmenopausal osteoporosis and osteoimmune research.

• Catalpol Mitigates Triptolide-Induced Liver Injury via SIRT1

  2026-06-04

  This study reveals that catalpol can significantly reduce hepatic glucose metabolism disorder and oxidative stress in triptolide-induced liver injury by activating the SIRT1/HIF-1α pathway. The findings offer mechanistic insight into drug-induced hepatotoxicity and highlight catalpol’s potential as a therapeutic strategy for managing triptolide-associated liver damage.

• Busulfan in Translational Models: Mechanisms, Limits, and Le

  2026-06-04

  This thought-leadership article explores Busulfan's mechanistic role as a DNA alkylating agent, its precision in senescence and germ cell ablation models, and how dual recombinase-mediated genetic tracing reshapes our understanding of germline biology. It bridges rigorous experimental evidence with strategic guidance for translational researchers, providing actionable protocol parameters and a nuanced outlook on modeling choice and interpretation.

• Imidazoline Antagonists Boost Insulin by Blocking β-Cell K+

  2026-06-03

  The reference study demonstrates that imidazoline antagonists of α2-adrenoceptors increase insulin secretion in vitro by directly inhibiting ATP-sensitive potassium channels in pancreatic β-cells, rather than by classical receptor antagonism. This mechanistic insight refines our understanding of insulinotropic drug action and guides future research in ion channel modulation for metabolic disease.

• Betaine Hydrochloride: Precision Reagent for Enzyme and Prot

  2026-06-03

  Betaine hydrochloride (carboxymethyl(trimethyl)azanium chloride) empowers metabolic enzyme and protease research with reproducible, high-purity workflows. Its water solubility, stability profile, and rigorous QC make it a cornerstone for advanced cell culture and molecular biology applications.

• Berbamine Hydrochloride: Targeting Ferroptosis Resistance in

  2026-06-02

  Explore how Berbamine hydrochloride, a potent NF-κB activity inhibitor, enables precision targeting of ferroptosis resistance in hepatocellular carcinoma. This in-depth analysis bridges translational science and workflow optimization, providing new research insights beyond assay protocols.

• Tiamulin (Thiamutilin): Structural Insights and Assay Innova

  2026-06-02

  Explore the molecular interactions of Tiamulin (Thiamutilin) at the ribosomal level and their implications for robust assay design and resistance surveillance. This article offers an advanced, practical perspective for researchers using Tiamulin in veterinary and translational applications.

• Dissecting Drug Responses in Cancer: In Vitro Methodological

  2026-06-01

  Schwartz's dissertation introduces refined in vitro drug evaluation methods that distinguish between proliferative arrest and cell death in cancer cells. This nuanced approach enhances the interpretation of anti-cancer compound efficacy and informs the selection of targeted therapies in preclinical research.

• Mianserin HCl as a 5-HT2 Antagonist: Insights from Controlle

  2026-06-01

  This article examines the landmark clinical trial establishing Mianserin HCl as an effective 5-HT2 receptor antagonist for depressive disorders. The study’s rigorous methodology and comparative design highlight both the antidepressant efficacy and improved tolerability profile of Mianserin HCl relative to amitriptyline, offering key insights for antidepressant research and receptor pharmacology.

• Dual Terminal Oxidase Inhibition Drives Potent TB Killing

  2026-05-31

  This study reveals that pretomanid, a bicyclic nitroimidazole derivative, exerts bactericidal activity against Mycobacterium tuberculosis by simultaneously inhibiting both cytochrome bcc:aa3 and bd oxidase respiratory branches. The findings clarify pretomanid’s unique dual mechanism and support new approaches for designing synergistic, resistance-limiting tuberculosis drug regimens.

455 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page